Atrophic gastritis is a condition in which the stomach lining slowly thins and loses the specialized cells it needs to produce acid and absorb nutrients. Unlike ordinary gastritis, which involves temporary inflammation, atrophic gastritis represents a permanent structural change. The cells that once lined the stomach are gradually replaced by tissue that resembles the intestinal lining, a process that unfolds over years or even decades.
How the Stomach Lining Changes
Your stomach lining contains millions of specialized cells. Among the most important are parietal cells, which produce stomach acid and a protein called intrinsic factor that your body needs to absorb vitamin B12. In atrophic gastritis, these cells are progressively destroyed. The tissue that replaces them looks and functions more like intestinal tissue, complete with cell types normally found only in the gut. This transformation is called intestinal metaplasia.
As this process advances, the stomach produces less and less acid. That might sound like a good thing, but stomach acid plays essential roles: it breaks down food, kills harmful bacteria, and activates digestive enzymes. Without enough acid, nutrient absorption suffers, and the door opens to a cascade of deficiencies.
The Two Types and Their Causes
Atrophic gastritis comes in two distinct forms, each driven by a different mechanism.
Environmental (Type B)
The more common form is caused by long-term infection with H. pylori bacteria. These bacteria burrow beneath the protective mucus layer of the stomach, exposing the lining to acidic digestive juices. Over many years, this chronic inflammation destroys glandular tissue, starting in the lower part of the stomach and gradually spreading. Risk factors include being over 70, eating a high-salt diet, smoking, and living in crowded conditions. Rates are highest in East Asian, Hispanic, and Latin American populations.
Autoimmune (Type A)
In autoimmune atrophic gastritis, the immune system produces antibodies that directly attack the stomach’s parietal cells. These antibodies target the acid-producing machinery of the cells and, in many cases, also attack intrinsic factor itself. Anti-parietal cell antibodies are found in 60 to 90 percent of people with this form, and anti-intrinsic factor antibodies in 50 to 70 percent. The damage concentrates in the upper portions of the stomach (the body and fundus), leaving the lower section relatively intact.
This form is more common in women, people of African American or Northern European descent, and those with other autoimmune conditions like Hashimoto’s thyroiditis, type 1 diabetes, Graves’ disease, vitiligo, or Addison disease. A family history of autoimmune gastritis also raises your risk.
Symptoms and What They Feel Like
Atrophic gastritis is notoriously quiet in its early stages. Many people have it for years without obvious digestive complaints. When symptoms do appear, they tend to fall into two categories: digestive and nutritional.
On the digestive side, you might notice a vague fullness after eating, nausea, or a dull ache in the upper abdomen. Some people experience bloating or a loss of appetite. These symptoms are easy to dismiss or attribute to other causes, which is part of why the condition often goes undiagnosed for a long time.
The nutritional consequences can be more dramatic. Because parietal cells produce intrinsic factor, their loss directly impairs vitamin B12 absorption. B12 deficiency builds gradually and can cause fatigue, weakness, pale skin, a smooth or sore tongue, numbness or tingling in the hands and feet, difficulty with balance, confusion, and memory problems. When B12 deficiency from autoimmune gastritis becomes severe enough to cause a specific type of anemia, the condition is called pernicious anemia. Iron deficiency is also common, since stomach acid is needed to convert dietary iron into a form the body can absorb.
How It’s Diagnosed
The gold standard for diagnosis is an upper endoscopy with biopsies. During this procedure, a thin camera is passed into the stomach, where the doctor can see visible changes: the lining appears pale, the normal folds of the stomach are flattened, and blood vessels that would normally be hidden become visible through the thinned tissue. Small tissue samples are taken from multiple sites in the stomach and examined under a microscope to confirm the loss of glandular cells and check for intestinal metaplasia.
Blood tests can provide supporting clues. Low B12 levels, iron deficiency anemia, elevated gastrin (a hormone that rises when the stomach can’t produce enough acid), and the presence of anti-parietal cell or anti-intrinsic factor antibodies all point toward the diagnosis. Researchers have studied blood markers like pepsinogen levels and ratios as potential screening tools, but their accuracy has proven inconsistent across populations, so they haven’t replaced endoscopy as the definitive test.
The Link to Stomach Cancer
One of the reasons atrophic gastritis matters beyond its nutritional effects is its connection to gastric cancer. The progression from normal stomach lining to atrophy, then to intestinal metaplasia, and potentially to precancerous changes and cancer is well established. The annual incidence of gastric cancer in people with chronic atrophic gastritis is estimated at 0.1 to 0.3 percent. That sounds small, but over 10 or 20 years the cumulative risk becomes meaningful. When precancerous changes (called dysplasia or intraepithelial neoplasia) are included, the annual rate of concerning findings can reach as high as 1.36 percent.
Not everyone with atrophic gastritis develops cancer. The risk depends on how widespread the atrophy is, whether intestinal metaplasia is present, and whether the underlying cause (particularly H. pylori infection) has been treated. People with atrophy limited to a small area of the stomach are at much lower risk than those with extensive changes involving both the upper and lower stomach.
Treatment and Management
Treatment depends on the cause. For the environmental form driven by H. pylori, the first step is eradicating the infection with a combination of antibiotics and acid-suppressing medications. Clearing the bacteria halts the inflammatory damage and may, in some cases, allow partial recovery of the stomach lining, though established intestinal metaplasia generally does not reverse.
For the autoimmune form, there is no way to stop the immune attack on parietal cells. Management focuses on replacing what the damaged stomach can no longer provide. Vitamin B12 supplementation is the cornerstone. Oral doses of 1 to 2 mg daily have been shown to be as effective as injections for correcting both anemia and neurological symptoms, though injections (typically given three times per week for two weeks initially) are sometimes preferred when deficiency is severe or neurological symptoms are present. If neurological deficits exist, injections may be given every other day for up to three weeks or until symptoms stop improving. Iron supplementation is also commonly needed.
Because of the cancer risk, surveillance endoscopy is recommended for people with confirmed atrophic gastritis and intestinal metaplasia. Current guidelines from the American Gastroenterological Association suggest that a repeat endoscopy with biopsies from both the upper and lower stomach may be considered every 3 to 5 years for people with incidentally discovered intestinal metaplasia, though the optimal interval remains uncertain. The decision is typically individualized, weighing factors like the extent of atrophy, family history of gastric cancer, and the patient’s preferences.
Living With Atrophic Gastritis
For most people, atrophic gastritis is a condition that requires ongoing monitoring rather than daily symptom management. Once B12 and iron levels are corrected, many of the most bothersome symptoms, particularly fatigue, neurological issues, and anemia, improve significantly. The key is making sure deficiencies don’t quietly return, which means regular blood work to check B12, iron, and blood counts.
Dietary adjustments can help with digestive symptoms. Smaller, more frequent meals tend to be easier on a stomach that produces less acid. Some people find that avoiding very fatty or spicy foods reduces discomfort. If you have the H. pylori-driven form, successfully treating the infection removes the ongoing trigger, though the structural changes already present in the stomach lining may persist and still warrant periodic monitoring.